NCT00626483View on ClinicalTrials.gov

Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 24, 2007

Primary Completion Date

July 6, 2016

Study Completion Date

July 6, 2016

Conditions
Malignant Neoplasms Brain
Interventions
BIOLOGICAL

RNA-loaded dendritic cell vaccine

Only one dose of DCs (2 x 10\^7) is being assessed.

DRUG

basiliximab

Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gary Archer Ph.D.

OTHER

NCT00626483 - Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia | Biotech Hunter | Biotech Hunter